Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition.

Jacobi J, Prignitz A, Büttner M, Korn K, Weidemann A, Hilgers KF, Heller K, Velden J, Knöll A, Wullich B, May C, Eckardt KU, Amann KU.

BMC Nephrol. 2013 Oct 2;14:207. doi: 10.1186/1471-2369-14-207.

2.

BK virus viremia in a well-HLA-matched kidney transplant population mainly on low-dose cyclosporine-based immunosuppression.

Helanterä I, Salmela K, Kyllönen L, Räisänen-Sokolowski A, Auvinen E, Mannonen L, Koskinen P, Lautenschlager I.

Clin Transplant. 2012 Nov-Dec;26(6):E596-601. doi: 10.1111/ctr.12040. Epub 2012 Oct 22.

PMID:
23083418
3.

Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia.

Gabardi S, Ramasamy S, Kim M, Klasek R, Carter D, Mackenzie MR, Chandraker A, Tan CS.

Transpl Infect Dis. 2015 Aug;17(4):536-43. doi: 10.1111/tid.12402. Epub 2015 Jun 26.

4.

Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy.

Radtke J, Dietze N, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.

Transpl Infect Dis. 2016 Dec;18(6):850-855. doi: 10.1111/tid.12611. Epub 2016 Nov 30.

PMID:
27639176
5.

Screening for BK viremia reduces but does not eliminate the risk of BK nephropathy: a single-center retrospective analysis.

Knight RJ, Gaber LW, Patel SJ, DeVos JM, Moore LW, Gaber AO.

Transplantation. 2013 Apr 15;95(7):949-54. doi: 10.1097/TP.0b013e31828423cd.

PMID:
23545506
6.
7.

BK virus infection in pediatric renal transplantation.

Zarauza Santoveña A, García Meseguer C, Martínez Mejía S, Alonso Melgar Á, Fernández Camblor C, Melgosa Hijosa M, Peña Carrión A, Espinosa Román L.

Transplant Proc. 2015 Jan-Feb;47(1):62-6. doi: 10.1016/j.transproceed.2014.11.020.

PMID:
25645771
8.

Monitoring of polyomavirus BK replication and impact of preemptive immunosuppression reduction in renal-transplant recipients in China: a 5-year single-center analysis.

Huang G, Wang CX, Zhang L, Fei JG, Deng SX, Qiu J, Li J, Chen GD, Fu Q, Chen LZ.

Diagn Microbiol Infect Dis. 2015 Jan;81(1):21-6. doi: 10.1016/j.diagmicrobio.2014.09.024. Epub 2014 Oct 2.

PMID:
25445121
9.

BK polyomavirus in solid organ transplantation.

Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice.

Am J Transplant. 2013 Mar;13 Suppl 4:179-88. doi: 10.1111/ajt.12110.

10.

Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy.

Schaub S, Hirsch HH, Dickenmann M, Steiger J, Mihatsch MJ, Hopfer H, Mayr M.

Am J Transplant. 2010 Dec;10(12):2615-23. doi: 10.1111/j.1600-6143.2010.03310.x.

11.

Association of treatment with 15-deoxyspergualin and BK virus nephropathy in kidney allograft recipients.

Shi Y, Moriyama T, Namba Y, Yamanaka M, Hanafuse T, Imamura R, Ichimaru N, Oka K, Kyo M, Tian Y, Takahara S, Ichikawa S, Okuyama A.

Clin Transplant. 2007 Jul-Aug;21(4):502-9.

PMID:
17645710
12.

Nephropathy Evolving Within the First Two Posttransplant Months With No Typical Cytopathic Lesions: Two Cases Presentation.

Perkowska-Ptasińska A, Dęborska-Materkowska D, Serwańska-Świętek M, Wszoła M, Kwiatkowski A, Durlik M.

Transplant Proc. 2016 Jun;48(5):1611-5. doi: 10.1016/j.transproceed.2016.03.007.

PMID:
27496456
13.

Conversion to mTOR-inhibitors with calcineurin inhibitor elimination or minimization reduces urinary polyomavirus BK load in kidney transplant recipients.

Yen CL, Tian YC, Wu HH, Weng CH, Chen YC, Tu KH, Liu SH, Lee CC, Lai PC, Fang JT, Hung CC, Yang CW, Li YJ.

J Formos Med Assoc. 2016 Jul;115(7):539-46. doi: 10.1016/j.jfma.2016.01.008. Epub 2016 Mar 16.

14.

Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy.

Saad ER, Bresnahan BA, Cohen EP, Lu N, Orentas RJ, Vasudev B, Hariharan S.

Transplantation. 2008 Mar 27;85(6):850-4. doi: 10.1097/TP.0b013e318166cba8.

PMID:
18360267
15.

Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.

Tohme FA, Kalil RS, Thomas CP.

Transpl Infect Dis. 2015 Feb;17(1):66-72. doi: 10.1111/tid.12347. Epub 2015 Jan 13.

PMID:
25582442
16.

BK virus nephritis after renal transplantation.

Hariharan S.

Kidney Int. 2006 Feb;69(4):655-62. Review.

17.

Factors and outcome in BK virus nephropathy in a Hispanic kidney transplant population.

Pérez-Torres D, Bertrán-Pasarell J, Santiago-Delpín E, González-Ramos M, Medina-Mangual S, Morales-Otero L, González-Caraballo Z.

Transpl Infect Dis. 2010 Feb;12(1):16-22. doi: 10.1111/j.1399-3062.2009.00458.x. Epub 2009 Oct 5.

PMID:
19804584
18.

BK virus nephropathy in renal transplant recipients in Kuwait: a preliminary report.

Nampoory MR, Johny KV, Pacsa A, Nair PM, Said T, Halim MA, Francis I, Samhan M, Mousawi M, Dalawi A, Szucs G, Al-Nakib W.

Transplant Proc. 2005 Sep;37(7):3048-50.

PMID:
16213300
19.

Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor.

Hässig A, Roos M, Etter A, Bossart W, Müller N, Schiesser M, Wüthrich RP, Fehr T.

Transpl Infect Dis. 2014 Feb;16(1):44-54. doi: 10.1111/tid.12153. Epub 2013 Oct 18.

PMID:
24134704
20.

Prevalence and clinical course of BK virus nephropathy in pancreas after kidney transplant patients.

Duclos AJ, Krishnamurthi V, Lard M, Poggio E, Kleeman M, Winans C, Fatica R, Nurko S.

Transplant Proc. 2006 Dec;38(10):3666-72.

PMID:
17175362

Supplemental Content

Support Center